Services
GLP-1 patient research & segmentation
A grounded understanding of who your patients are and what matters to them. Everything we recommend starts here: what GLP-1 patients respond to, where their pain points are, and how this community actually talks about treatment, cost, side effects, and trust.
Most GLP-1 marketing misses because it's built on assumptions about a patient population that is changing fast. Research replaces those assumptions — so acquisition, retention, and product decisions are made about the patients you really have, not the ones you imagine.
- Telehealth platforms
- Data platforms
- Review & aggregator sites
- Consumer brands
What an engagement covers
Audience segmentation
Who your patients are — segments, motivations, and where each is in their GLP-1 journey.
Pain-point mapping
The friction that drives patients away — from onboarding through refills — seen from their side.
Language & trust signals
The words patients use and the signals they look for before they'll trust a brand with their care.
Decisions, informed
Findings translated into implications for acquisition, retention, and product — not a report that sits.
Signs this is the engagement you need
- Patients sign up but don't stay, and nobody can say why with confidence
- Your roadmap and marketing are built on assumptions no one has tested against real patients
- Different teams describe your patient in contradictory ways
How it works
How we'll work together
Every engagement is shaped around your situation — a single strategy session, an ongoing advisory relationship, or on-site work. We'll find the right fit together on a complimentary consultation.
01
Complimentary consultation
We talk through where you are and what you need.
02
Shaped around you
We tailor the engagement, and the investment, to your situation.
03
We begin the work
A single strategy session, ongoing advisory, or on-site work.
Related
Let's build something your patients trust.
Start with a complimentary consultation. If we're a good fit, we'll take it from there.